immunomodulator

aTyr Pharma Prioritizes Efzofitimod as FDA Phase 3 Feedback Approaches

SAN DIEGO, August 7, 2026 aTyr Pharma reported its second quarter 2026 results and announced a corporate restructuring designed...

By cGxPwire Editor
August 10, 2026

Bio-Pharma

Kiora Pharmaceuticals Advances Dual Phase 2 Retinal Trials with FDA-Backed Innovation

Dateline — Encinitas, California, November 8, 2024:Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its third-quarter 2024 results alongside significant progress...

By cGxPwire Editor
November 9, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

immunomodulator

aTyr Pharma Prioritizes Efzofitimod as FDA Phase 3 Feedback Approaches

Kiora Pharmaceuticals Advances Dual Phase 2 Retinal Trials with FDA-Backed Innovation